Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition [REVIEW ARTICLE]
Conclusion
Level 1 evidence exists to support the use of nivolumab as second-line treatment of patients with squamous advanced NSCLC, as well as in select patients with nonsquamous disease. Benefits remain unknown in patients with targetable driver mutations, and use of PD-L1 expression to guide therapy remains controversial. Results from ongoing randomized trials evaluating biomarkers and other checkpoint inhibitors will further our understanding of this rapidly evolving area of oncology.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Melosky, Chu, Juergens, Leighl, McLeod, Hirsh Tags: Chemotherapy, Basic Science, Pathology, Lung, Immunology/Immunobiology REVIEW ARTICLE Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Docetaxel | Lung Cancer | Non-Small Cell Lung Cancer | Pathology | Science | Taxotere